SCHEMBL4338564

SCHEMBL4338564

O=P(O)(O)NP(=O)(O)Oc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.59
KDM4E B2RXH2 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HTT P42858 2/20 0.43
ANPEP P15144 2/20 0.42
LAP3 P28838 2/20 0.42
LMNA P02545 2/20 0.41
RECQL P46063 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PKM P14618 1/20 0.40
MMP2 P08253 1/20 0.40
MMP8 P22894 1/20 0.40
MMP14 P50281 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22323438 0.91 SRC (0.64) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL25348379 0.81 SRC (0.61) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL5594628 0.79 SRC (0.59) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL9583781 0.78 SRC (0.70) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL9115028 0.78 KDM4E (0.66) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL28144672 0.77 SRC (0.52) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL4272051 0.75 SRC (0.73) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL6686008 0.75 SRC (0.73) SRCKDM4EL3MBTL1TDP1CYP2C9
SCHEMBL37038 0.75 SRC (0.73) SRCKDM4EL3MBTL1TDP1CYP2C9
Phenyl Dihydrogen Phosphate SCHEMBL20263 0.75 SRC (1.00) SRCKDM4EL3MBTL1TDP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815834-B2 Use of dendrimers to stimulate cell growth CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-08-26 US disclosed
EP-1771548-B1 USE OF DENDRIMERS TO STIMULATE CELL GROWTH CENTRE NAT RECH SCIENT (FR) 2012-06-27 EP disclosed
US-20090142316-A1 Use of Dendrimers to Stimulate Cell Growth CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-06-04 US disclosed
EP-1771548-A1 USE OF DENDRIMERS TO STIMULATE CELL GROWTH CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-04-11 EP disclosed
WO-2006024769-A1 USE OF DENDRIMERS TO STIMULATE CELL GROWTH CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090142316-A1 Use of Dendrimers to Stimulate Cell Growth HDGF, CD40LG, PPIP5K2 SRC 846/4885KDM4E 4303/4885L3MBTL1 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.